Remdesivir has three randomised controlled trials all of which indicate statistically significant effects, and there don't seem to be any credible challenges to these trials results. Currently given the concerns about the irregularities in the data in it's existing trials, Ivermectin has none.
[1] https://www.sciencedirect.com/science/article/pii/S016635422...
> Even though ivermectin had no effect on viral load, SARS-Cov-2-associated pathology was greatly attenuated. IVM had a sex-dependent and compartmentalized immunomodulatory effect, preventing clinical deterioration and reducing olfactory deficit in infected animals. Importantly, ivermectin dramatically reduced the Il-6/Il-10 ratio in lung tissue, which likely accounts for the more favorable clinical presentation in treated animals. Our data support IVM as a promising anti-COVID-19 drug candidate.
However, I've also heard there's a new study coming out from Gilead that demonstrates Remdesivir is highly effective when administered in early treatment.
So perhaps the efficacy depends when treatment is given. And if that's the case, then meta-studies actually become very important, because they can reveal hidden factors like dosage, demographic, when to administer treatment, etc.